Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)

NCT00988208 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT00988208
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00988208 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)
Lead sponsor
Celgene
Phase
Phase 3
Overall status
Completed
Start date
November 11, 2009
Completion date
November 28, 2016
Enrollment
1,059 (actual)
Sites
210

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer